

MD Anderson Ovarian SPORE publications – 2017

1. Bednar EM, Oakley HD, Sun CC, Burke CC, Munsell MF, Westin SN, Lu KH. **A universal genetic testing initiative for patients with high-grade, non-mucinous epithelial ovarian cancer and the implications for cancer treatment.** *Gynecol Oncol* 146(2):399-404, 2017. PMID: 28610746.
2. Brusco LL, Wathoo C, Mills Shaw KR, Holla VR, Bailey AM, Johnson AM, Khotskaya YB, Litzemberger BC, Sanchez NS, Zeng J, Bernstam EV, Eng C, Kee BK, Amaria RN, Routbort MJ, Mills GB, Mendelsohn J, Meric-Bernstam F. **Physician interpretation of genomic test results and treatment selection.** *Cancer, e-Pub* 11/2017. PMID: 29165790.
3. Cho MS, Noh K, Haemmerle M, Li D, Park H, Hu Q, Hisamatsu T, Mitamura T, Mak SLC, Kunapuli S, Ma Q, Sood AK, Afshar-Kharghan V. **Role of ADP receptors on platelets in the growth of ovarian cancer.** *Blood* 130(10):1235-1242, 2017. PMCID: PMC5606004.
4. Chung JF, Lee SJ, Sood AK. **Immunological consequences of ageing microvascular hemodynamic changes in view of cancer development and treatment.** *Oncotarget* 8(40):69047-69061, 2017. PMCID: PMC5620320.
5. Coleman RL, Brady MF, Herzog TJ, Sabbatini P, Armstrong DK, Walker JL, Kim BG, Fujiwara K, Tewari KS, O'Malley DM, Davidson SA, Rubin SC, DiSilvestro P, Basen-Engquist K, Huang H, Chan JK, Spirtos NM, Ashfaq R, Mannel RS. **Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial.** *Lancet Oncol* 18(6):779-791, 2017. PMCID: PMC5715461.
6. Coleman RL, Oza AM, Lorusso D, Aghajanian C, Oaknin A, Dean A, Colombo N, Weberpals JI, Clamp A, Scambia G, Leary A, Holloway RW, Gancedo MA, Fong PC, Goh JC, O'Malley DM, Armstrong DK, Garcia-Donas J, Swisher EM, Floquet A, Konecny GE, McNeish IA, Scott CL, Cameron T, Maloney L, Isaacson J, Goble S, Grace C, Harding TC, Raponi M, Sun J, Lin KK, Giordano H, Ledermann JA, ARIEL3 investigators. **Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial.** *Lancet* 390(10106):1949-1961, 2017. PMID: 28916367.
7. Corzo C, Iniesta MD, Patrono MG, Lu KH, Ramirez PT. **Role of Fallopian Tubes in the Development of Ovarian Cancer.** *J Minim Invasive Gynecol* 24(2):230-234, 2017. PMID: 28007588.
8. Court KA, Hatakeyama H, Wu SY, Lingegowda MS, Rodríguez-Aguayo C, López-Berestein G, Ju-Seog L, Rinaldi C, Juan EJ, Sood AK, Torres-Lugo M. **HSP70 Inhibition Synergistically Enhances the Effects of Magnetic Fluid Hyperthermia in Ovarian Cancer.** *Mol Cancer Ther* 16(5):966-976, 2017. PMID: 28223424.
9. Cuneo MG, Schrepf A, Slavich GM, Thaker PH, Goodheart M, Bender D, Cole SW, Sood AK, Lutgendorf SK. **Diurnal cortisol rhythms, fatigue and psychosocial factors in five-year survivors of ovarian cancer.** *Psychoneuroendocrinology* 84:139-142, 2017. PMCID: PMC5575993.
10. Dalton HJ, Fleming ND, Sun CC, Bhosale P, Schmeler KM, Gershenson DM. **Activity of bevacizumab-containing regimens in recurrent low-grade serous ovarian or peritoneal cancer: A single institution experience.** *Gynecol Oncol* 145(1):37-40, 2017. PMID: 28139261.
11. Dalton HJ, Pradeep S, McGuire M, Hailemichael Y, Ma S, Lyons Y, Armaiz-Pena GN, Previs RA, Hansen JM, Rupaimoole R, Gonzalez-Villasana V, Cho MS, Wu SY, Mangala LS, Jennings NB, Hu W, Langley R, Mu H, Andreeff M, Bar-Eli M, Overwijk W, Ram P, Lopez-Berestein G, Coleman RL, Sood AK. **Macrophages Facilitate Resistance to Anti-VEGF Therapy by Altered VEGFR Expression.** *Clin Cancer Res* 23(22):7034-7046, 2017. PMCID: PMC5690831.

12. Denizli M, Aslan B, Mangala LS, Jiang D, Rodriguez-Aguayo C, Lopez-Berestein G, Sood AK. **Chitosan Nanoparticles for miRNA Delivery**. *Methods Mol Biol* 1632:219-230, 2017. PMID: 28730442.
13. Essel KG, Bruegl A, Gershenson DM, Ramondetta LM, Naumann RW, Brown J. **Salvage chemotherapy for gestational trophoblastic neoplasia: Utility or futility?** *Gynecol Oncol* 146(1):74-80, 2017. PMID: 28473205.
14. Fleming ND, Coleman RL, Tung C, Westin SN, Hu W, Sun Y, Bhosale P, Munsell MF, Sood AK. **Phase II trial of bevacizumab with dose-dense paclitaxel as first-line treatment in patients with advanced ovarian cancer**. *Gynecol Oncol* 147(1):41-46, 2017. PMCID: PMC5605462.
15. Gangwar R, Meena AS, Shukla PK, Nagaraja AS, Dorniak PL, Pallikuth S, Waters CM, Sood A, Rao R. **Calcium-mediated oxidative stress: a common mechanism in tight junction disruption by different types of cellular stress**. *Biochem J* 474(5):731-749, 2017. PMCID: PMC5723146.
16. George E, Kim H, Krepler C, Wenz B, Makvandi M, Tanyi JL, Brown E, Zhang R, Brafford P, Jean S, Mach RH, Lu Y, Mills GB, Herlyn M, Morgan M, Zhang X, Soslow R, Drapkin R, Johnson N, Zheng Y, Cotsarelis G, Nathanson KL, Simpkins F. **A patient-derived-xenograft platform to study BRCA-deficient ovarian cancers**. *JCI Insight* 2(1):e89760, 2017. PMCID: PMC5214535.
17. Gershenson DM, Bodurka DC, Coleman RL, Lu KH, Malpica A, Sun CC. **Hormonal Maintenance Therapy for Women With Low-Grade Serous Cancer of the Ovary or Peritoneum**. *J Clin Oncol* 35(10):1103-1111, 2017. PMCID: PMC5455356.
18. Gershenson DM. **Management of borderline ovarian tumours**. *Best Pract Res Clin Obstet Gynaecol* 41:49-59, 2017. PMID: 27780698.
19. Haemmerle M, Taylor ML, Gutschner T, Pradeep S, Cho MS, Sheng J, Lyons YM, Nagaraja AS, Dood RL, Wen Y, Mangala LS, Hansen JM, Rupaimoole R, Gharpure KM, Rodriguez-Aguayo C, Yim SY, Lee JS, Ivan C, Hu W, Lopez-Berestein G, Wong ST, Karlan BY, Levine DA, Liu J, Afshar-Kharghan V, Sood AK. **Platelets reduce anoikis and promote metastasis by activating YAP1 signaling**. *Nat Commun* 8(1):310, 2017. PMCID: PMC5566477.
20. Harjes U, Bridges E, Gharpure KM, Roxanis I, Sheldon H, Miranda F, Mangala LS, Pradeep S, Lopez-Berestein G, Ahmed A, Fielding B, Sood AK, Harris AL. **Antiangiogenic and tumour inhibitory effects of downregulating tumour endothelial FABP4**. *Oncogene* 36(7):912-921, 2017. PMCID: PMC5318662.
21. Herzog TJ, Ison G, Alvarez RD, Balasubramaniam S, Armstrong DK, Beaver JA, Ellis A, Tang S, Ford P, McKee A, Gershenson DM, Kim G, Monk BJ, Pazdur R, Coleman RL. **FDA ovarian cancer clinical trial endpoints workshop: A Society of Gynecologic Oncology White Paper**. *Gynecol Oncol* 147(1):3-10, 2017. PMID: 28844539.
22. Hill SM, Nesser NK, Johnson-Camacho K, Jeffress M, Johnson A, Boniface C, Spencer SE, Lu Y, Heiser LM, Lawrence Y, Pande NT, Korkola JE, Gray JW, Mills GB, Mukherjee S, Spellman PT. **Context Specificity in Causal Signaling Networks Revealed by Phosphoprotein Profiling**. *Cell Syst* 4(1):73-83.e10, 2017. PMCID: PMC5279869.
23. Holla VR, Elamin YY, Bailey AM, Johnson AM, Litzenburger BC, Khotskaya YB, Sanchez NS, Zeng J, Shufean MA, Shaw KR, Mendelsohn J, Mills GB, Meric-Bernstam F, Simon GR. **ALK: a tyrosine kinase target for cancer therapy**. *Cold Spring Harb Mol Case Stud* 3(1):a001115, 2017. PMCID: PMC5171696.
24. Hou D, Xu G, Zhang C, Li B, Qin J, Hao X, Liu Q, Zhang X, Liu J, Wei J, Gong Y, Liu Z, Shao C. **Berberine induces oxidative DNA damage and impairs homologous recombination repair in ovarian cancer cells to confer increased sensitivity to PARP inhibition**. *Cell Death Dis* 8(10):e3070, 2017. PMCID: PMC5680592.

25. Hu Q, Cho MS, Thiagarajan P, Aung FM, Sood AK, Afshar-Kharghan V. **A small amount of cyclooxygenase 2 (COX2) is constitutively expressed in platelets.** *Platelets* 28(1):99-102, 2017. PMID: PMC5310196.
26. Hu Q, Hisamatsu T, Haemmerle M, Cho MS, Pradeep S, Rupaimoole R, Rodriguez-Aguayo C, Lopez-Berestein G, Wong STC, Sood AK, Afshar-Kharghan V. **Role of Platelet-Derived Tgf β 1 in the Progression of Ovarian Cancer.** *Clin Cancer Res* 23(18):5611-5621, 2017. PMID: PMC5600833.
27. Janku F, Zhang S, Waters J, Liu L, Huang HJ, Subbiah V, Hong DS, Karp DD, Fu S, Cai X, Ramzanali NM, Madwani K, Cabrilo G, Andrews DL, Zhao Y, Javle M, Kopetz ES, Luthra R, Kim HJ, Gnerre S, Satya RV, Chuang HY, Kruglyak KM, Toung J, Zhao C, Shen R, Heymach JV, Meric-Bernstam F, Mills GB, Fan JB, Salathia NS. **Development and Validation of an Ultradeep Next-Generation Sequencing Assay for Testing of Plasma Cell-Free DNA from Patients with Advanced Cancer.** *Clin Cancer Res* 23(18):5648-5656, 2017. PMID: PMC5600825.
28. Jiang Y, Yan F, Liang L, Wan Y, Liu J, Cheng W. **Meta-analysis demonstrates no association between p16 ink4a promoter methylation and epithelial ovarian cancer.** *Arch Gynecol Obstet* 295(3):697-704, 2017. PMID: 28000027.
29. Jinesh GG, Manyam GC, Mmeje CO, Baggerly KA, Kamat AM. **Surface PD-L1, E-cadherin, CD24, and VEGFR2 as markers of epithelial cancer stem cells associated with rapid tumorigenesis.** *Sci Rep* 7(1):9602, 2017. PMID: PMC5575243.
30. Kanlikilicer P, Ozpolat B, Aslan B, Bayraktar R, Gurbuz N, Rodriguez-Aguayo C, Bayraktar E, Denizli M, Gonzalez-Villasana V, Ivan C, Lokesh GLR, Amero P, Catuogno S, Haemmerle M, Wu SY, Mitra R, Gorenstein DG, Volk DE, de Franciscis V, Sood AK, Lopez-Berestein G. **Therapeutic Targeting of AXL Receptor Tyrosine Kinase Inhibits Tumor Growth and Intraperitoneal Metastasis in Ovarian Cancer Models.** *Mol Ther Nucleic Acids* 9:251-262, 2017. PMID: PMC5675720.
31. Kar SP, Adler E, Tyrer J, Hazelett D, Anton-Culver H, Bandera EV, Beckmann MW, Berchuck A, Bogdanova N, Brinton L, Butzow R, Campbell I, Carty K, Chang-Claude J, Cook LS, Cramer DW, Cunningham JM, Dansonka-Mieszkowska A, Doherty JA, Dörk T, Dürst M, Eccles D, Fasching PA, Flanagan J, Gentry-Maharaj A, Glasspool R, Goode EL, Goodman MT, Gronwald J, Heitz F, Hildebrandt MA, Høgdall E, Høgdall CK, Huntsman DG, Jensen A, Karlan BY, Kelemen LE, Kiemeny LA, Kjaer SK, Kupryjanczyk J, Lambrechts D, Levine DA, Li Q, Lissowska J, Lu KH, Lubiński J, Massuger LF, McGuire V, McNeish I, Menon U, Modugno F, Monteiro AN, Moysich KB, Ness RB, Nevanlinna H, Paul J, Pearce CL, Pejovic T, Permuth JB, Phelan C, Pike MC, Poole EM, Ramus SJ, Risch HA, Rossing MA, Salvesen HB, Schildkraut JM, Sellers TA, Sherman M, Siddiqui N, Sieh W, Song H, Southey M, Terry KL, Tworoger SS, Walsh C, Wentzensen N, Whitemore AS, Wu AH, Yang H, Zheng W, Ziogas A, Freedman ML, Gayther SA, Pharoah PD, Lawrenson K. **Enrichment of putative PAX8 target genes at serous epithelial ovarian cancer susceptibility loci.** *Br J Cancer* 116(4):524-535, 2017. PMID: PMC5318969.
32. Khotskaya YB, Mills GB, Mills Shaw KR. **Next-Generation Sequencing and Result Interpretation in Clinical Oncology: Challenges of Personalized Cancer Therapy.** *Annu Rev Med* 68:113-125, 2017. PMID: 27813876.
33. Kondrashova O, Nguyen M, Shield-Artin K, Tinker AV, Teng NNH, Harrell MI, Kuiper MJ, Ho GY, Barker H, Jasin M, Prakash R, Kass EM, Sullivan MR, Brunette GJ, Bernstein KA, Coleman RL, Floquet A, Friedlander M, Kichenadasse G, O'Malley DM, Oza A, Sun J, Robillard L, Maloney L, Bowtell D, Giordano H, Wakefield MJ, Kaufmann SH, Simmons AD, Harding TC, Raponi M, McNeish IA, Swisher EM, Lin KK, Scott CL, AOCs Study Group. **Secondary Somatic Mutations Restoring RAD51C and RAD51D Associated with Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma.** *Cancer Discov* 7(9):984-998, 2017. PMID: PMC5612362.
34. Krop I, Ismaila N, Andre F, Bast RC, Barlow W, Collyar DE, Hammond ME, Kuderer NM, Liu MC, Mennel RG, Van Poznak C, Wolff AC, Stearns V. **Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical**

Oncology Clinical Practice Guideline Focused Update. J Clin Oncol 35(24):2838-2847, 2017. PMID: 28692382.

35. Kumar MNVR, Sood AK. **Editorial - Metronomic chemotherapy.** Cancer Lett 400:203, 2017. PMID: 28315702.
36. Le TN, Harvey RE, Kim CK, Brown J, Coleman RL, Smith JA. **A retrospective evaluation of activity of gemcitabine/platinum regimens in the treatment of recurrent ovarian cancer.** Gynecol Oncol Res Pract 4:16, 2017. PMID: PMC5684736.
37. Li J, Akbani R, Zhao W, Lu Y, Weinstein JN, Mills GB, Liang H. **Explore, Visualize, and Analyze Functional Cancer Proteomic Data Using the Cancer Proteome Atlas.** Cancer Res 77(21):e51-e54, 2017. PMID: PMC5679242.
38. Li J, Zhao W, Akbani R, Liu W, Ju Z, Ling S, Vellano CP, Roebuck P, Yu Q, Eterovic AK, Byers LA, Davies MA, Deng W, Gopal YN, Chen G, von Euw EM, Slamon D, Conklin D, Heymach JV, Gazdar AF, Minna JD, Myers JN, Lu Y, Mills GB, Liang H. **Characterization of Human Cancer Cell Lines by Reverse-phase Protein Arrays.** Cancer Cell 31(2):225-239, 2017. PMID: PMC5501076.
39. Li L, Zheng H, Huang Y, Huang C, Zhang S, Tian J, Li P, Sood AK, Zhang W, Chen K. **DNA methylation signatures and coagulation factors in the peripheral blood leucocytes of epithelial ovarian cancer.** Carcinogenesis 38(8):797-805, 2017. PMID: 28637314.
40. Lutgendorf SK, Shinn E, Carter J, Leighton S, Baggerly K, Guindani M, Fellman B, Matzo M, Slavich GM, Goodman MT, Tew W, Lester J, Moore KM, Karlan BY, Levine DA, Sood AK. **Quality of life among long-term survivors of advanced stage ovarian cancer: A cross-sectional approach.** Gynecol Oncol 146(1):101-108, 2017. PMID: PMC5618102.
41. Luthra R, Patel KP, Routbort MJ, Broaddus RR, Yau J, Simien C, Chen W, Hatfield DZ, Medeiros LJ, Singh RR. **A Targeted High-Throughput Next-Generation Sequencing Panel for Clinical Screening of Mutations, Gene Amplifications, and Fusions in Solid Tumors.** J Mol Diagn 19(2):255-264, 2017. PMID: 28017569.
42. Lyons YA, Pradeep S, Wu SY, Haemmerle M, Hansen JM, Wagner MJ, Villar-Prados A, Nagaraja AS, Dood RL, Previs RA, Hu W, Zhao Y, Mak DH, Xiao Z, Melendez BD, Lizee GA, Mercado-Urbe I, Baggerly KA, Hwu P, Liu J, Overwijk WW, Coleman RL, Sood AK. **Macrophage depletion through colony stimulating factor 1 receptor pathway blockade overcomes adaptive resistance to anti-VEGF therapy.** Oncotarget 8(57):96496-96505, 2017. PMID: PMC5722500.
43. Matsuo K, Machida H, Takiuchi T, Grubbs BH, Roman LD, Sood AK, Gershenson DM. **Role of hysterectomy and lymphadenectomy in the management of early-stage borderline ovarian tumors.** Gynecol Oncol 144(3):496-502, 2017. PMID: 28131526.
44. Matulonis UA, Wulf GM, Barry WT, Birrer M, Westin SN, Farooq S, Bell-McGuinn KM, Obermayer E, Whalen C, Spagnoletti T, Luo W, Liu H, Hok RC, Aghajanian C, Solit DB, Mills GB, Taylor BS, Won H, Berger MF, Palakurthi S, Liu J, Cantley LC, Winer E. **Phase I dose escalation study of the PI3kinase pathway inhibitor BKM120 and the oral poly (ADP ribose) polymerase (PARP) inhibitor olaparib for the treatment of high-grade serous ovarian and breast cancer.** Ann Oncol 28(3):512-518, 2017. PMID: 27993796.
45. McGrail DJ, Lin CC, Garnett J, Liu Q, Mo W, Dai H, Lu Y, Yu Q, Ju Z, Yin J, Vellano CP, Hennessy B, Mills GB, Lin SY. **Improved prediction of PARP inhibitor response and identification of synergizing agents through use of a novel gene expression signature generation algorithm.** NPJ Syst Biol Appl 3:8, 2017. PMID: PMC5445594.

46. Menter DG, Kopetz S, Hawk E, Sood AK, Loree JM, Gresele P, Honn KV. **Platelet "first responders" in wound response, cancer, and metastasis.** *Cancer Metastasis Rev* 36(2):199-213, 2017. PMID: PMC5709140.
47. Mitra S, Montgomery JE, Kolar MJ, Li G, Jeong KJ, Peng B, Verdine GL, Mills GB, Moellering RE. **Stapled peptide inhibitors of RAB25 target context-specific phenotypes in cancer.** *Nat Commun* 8(1):660, 2017. PMID: PMC5610242.
48. Nagaraja AS, Dood RL, Armaiz-Pena G, Kang Y, Wu SY, Allen JK, Jennings NB, Mangala LS, Pradeep S, Lyons Y, Haemmerle M, Gharpure KM, Sadaoui NC, Rodriguez-Aguayo C, Ivan C, Wang Y, Baggerly K, Ram P, Lopez-Berestein G, Liu J, Mok SC, Cohen L, Lutgendorf SK, Cole SW, Sood AK. **Adrenergic-mediated increases in INHBA drive CAF phenotype and collagens.** *JCI Insight* 2(16), e-Pub 8/2017. PMID: PMC5621917.
49. Ng CS, Zhang Z, Lee SI, Marques HS, Burgers K, Su F, Bauza J, Mannel RS, Walker JL, Huh WK, Rubin SC, DiSilvestro P, Martin LP, Chan JK, Bookman MA, Coleman RL, Lee TY. **CT Perfusion as an Early Biomarker of Treatment Efficacy in Advanced Ovarian Cancer: An ACRIN and GOG Study.** *Clin Cancer Res* 23(14):3684-3691, 2017. PMID: PMC5720368.
50. Noh K, Mangala LS, Han HD, Zhang N, Pradeep S, Wu SY, Ma S, Mora E, Rupaimoole R, Jiang D, Wen Y, Shahzad MMK, Lyons Y, Cho M, Hu W, Nagaraja AS, Haemmerle M, Mak CSL, Chen X, Gharpure KM, Deng H, Xiong W, Kingsley CV, Liu J, Jennings N, Birrer MJ, Bouchard RR, Lopez-Berestein G, Coleman RL, An Z, Sood AK. **Differential Effects of EGFL6 on Tumor versus Wound Angiogenesis.** *Cell Rep* 21(10):2785-2795, 2017. PMID: PMC5749980.
51. Oliver KE, Brady WE, Birrer M, Gershenson DM, Fleming G, Copeland LJ, Tewari K, Argenta PA, Mannel RS, Secord AA, Stephan JM, Mutch DG, Stehman FB, Muggia FM, Rose PG, Armstrong DK, Bookman MA, Burger RA, Farley JH. **An evaluation of progression free survival and overall survival of ovarian cancer patients with clear cell carcinoma versus serous carcinoma treated with platinum therapy: An NRG Oncology/Gynecologic Oncology Group experience.** *Gynecol Oncol* 147(2):243-249, 2017. PMID: PMC5697899.
52. Oza AM, Tinker AV, Oaknin A, Shapira-Frommer R, McNeish IA, Swisher EM, Ray-Coquard I, Bell-McGuinn K, Coleman RL, O'Malley DM, Leary A, Chen LM, Provencher D, Ma L, Brenton JD, Konecny GE, Castro CM, Giordano H, Maloney L, Goble S, Lin KK, Sun J, Raponi M, Rolfe L, Kristeleit RS. **Antitumor activity and safety of the PARP inhibitor rucaparib in patients with high-grade ovarian carcinoma and a germline or somatic BRCA1 or BRCA2 mutation: Integrated analysis of data from Study 10 and ARIEL2.** *Gynecol Oncol* 147(2):267-275, 2017. PMID: 28882436.
53. Pan Y, Robertson G, Pedersen L, Lim E, Hernandez-Herrera A, Rowat AC, Patil SL, Chan CK, Wen Y, Zhang X, Basu-Roy U, Mansukhani A, Chu A, Sipahimalani P, Bowlby R, Brooks D, Thiessen N, Coarfa C, Ma Y, Moore RA, Schein JE, Mungall AJ, Liu J, Pecot CV, Sood AK, Jones SJ, Marra MA, Gunaratne PH. **Correction: miR-509-3p is clinically significant and strongly attenuates cellular migration and multi-cellular spheroids in ovarian cancer.** *Oncotarget* 8(10):17406, 2017. PMID: PMC5370050.
54. Phelan CM, Kuchenbaecker KB, Tyrer JP, Kar SP, Lawrenson K, Winham SJ, Dennis J, Pirie A, Riggan MJ, Chornokur G, Earp MA, Lyra PC Jr, Lee JM, Coetzee S, Beesley J, McGuffog L, Soucy P, Dicks E, Lee A, Barrowdale D, Lecarpentier J, Leslie G, Aalfs CM, Aben KKH, Adams M, Adlard J, Andrulis IL, Anton-Culver H, Antonenkova N, AOCs study group., Aravantinos G, Arnold N, Arun BK, Arver B, Azzollini J, Balmaña J, Banerjee SN, Barjhoux L, Barkardottir RB, Bean Y, Beckmann MW, Beeghly-Fadiel A, Benitez J, Bermisheva M, Bernardini MQ, Birrer MJ, Bjorge L, Black A, Blankstein K, Blok MJ, Bodelon C, Bogdanova N, Bojesen A, Bonanni B, Borg Å, Bradbury AR, Brenton JD, Brewer C, Brinton L, Broberg P, Brooks-Wilson A, Bruinsma F, Brunet J, Buecher B, Butzow R, Buys SS, Caldes T, Caligo MA, Campbell I, Cannioto R, Carney ME, Cescon T, Chan SB, Chang-Claude J, Chanock S, Chen XQ, Chiew YE, Chiquette J, Chung WK, Claes KBM, Conner T, Cook LS, Cook J, Cramer DW, Cunningham JM, D'Aloisio AA, Daly MB, Damiola F, Damirovna SD, Dansonka-Mieszkowska A, Dao F, Davidson R, DeFazio A, Delnatte C, Doheny KF, Diez O, Ding YC, Doherty JA, Domchek SM, Dorfling CM, Dörk T, Dossus L,

Duran M, Dürst M, Dworniczak B, Eccles D, Edwards T, Eeles R, Eilber U, Ejlersen B, Ekici AB, Ellis S, Elvira M, EMBRACE Study., Eng KH, Engel C, Evans DG, Fasching PA, Ferguson S, Ferrer SF, Flanagan JM, Fogarty ZC, Fortner RT, Fostira F, Foulkes WD, Fountzilias G, Fridley BL, Friebel TM, Friedman E, Frost D, Ganz PA, Garber J, García MJ, Garcia-Barberan V, Gehrig A, GEMO Study Collaborators., Gentry-Maharaj A, Gerdes AM, Giles GG, Glasspool R, Glendon G, Godwin AK, Goldgar DE, Goranova T, Gore M, Greene MH, Gronwald J, Gruber S, Hahnen E, Haiman CA, Håkansson N, Hamann U, Hansen TVO, Harrington PA, Harris HR, Hauke J, HEBON Study., Hein A, Henderson A, Hildebrandt MAT ... [Lu KH, Wu X]. **Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer.** *Nat Genet* 49(5):680-691, 2017. PMID: PMC5612337.

55. Pi F, Zhang H, Li H, Thiviyanathan V, Gorenstein DG, Sood AK, Guo P. **RNA nanoparticles harboring annexin A2 aptamer can target ovarian cancer for tumor-specific doxorubicin delivery.** *Nanomedicine* 13(3):1183-1193, 2017. PMID: PMC5426907.
56. Previs RA, Armaiz-Pena GN, Ivan C, Dalton HJ, Rupaimoole R, Hansen JM, Lyons Y, Huang J, Haemmerle M, Wagner MJ, Gharpure KM, Nagaraja AS, Filant J, McGuire MH, Noh K, Dorniak PL, Linesch SL, Mangala LS, Pradeep S, Wu SY, Sood AK. **Role of YAP1 as a Marker of Sensitivity to Dual AKT and P70S6K Inhibition in Ovarian and Uterine Malignancies.** *J Natl Cancer Inst* 109(7), 2017. PMID: 28376174.
57. Pu T, Xiong L, Liu Q, Zhang M, Cai Q, Liu H, Sood AK, Li G, Kang Y, Xu C. **Delineation of retroperitoneal metastatic lymph nodes in ovarian cancer with near-infrared fluorescence imaging.** *Oncol Lett* 14(3):2869-2877, 2017. PMID: PMC5588176.
58. Rabinowicz N, Mangala LS, Brown KR, Checa-Rodriguez C, Castiel A, Moskovich O, Zarfati G, Trakhtenbrot L, Levy-Barda A, Jiang D, Rodriguez-Aguayo C, Pradeep S, van Praag Y, Lopez-Berestein G, David A, Novikov I, Huertas P, Rottapel R, Sood AK, Izraeli S. **Targeting the centriolar replication factor STIL synergizes with DNA damaging agents for treatment of ovarian cancer.** *Oncotarget* 8(16):27380-27392, 2017. PMID: PMC5432342.
59. Randall LM, Pothuri B, Swisher EM, Diaz JP, Buchanan A, Witkop CT, Bethan Powell C, Smith EB, Robson ME, Boyd J, Coleman RL, Lu K. **Multi-disciplinary summit on genetics services for women with gynecologic cancers: A Society of Gynecologic Oncology White Paper.** *Gynecol Oncol* 146(2):217-224, 2017. PMID: 28596016.
60. Rashed MH, Kanlikilicer P, Rodriguez-Aguayo C, Pichler M, Bayraktar R, Bayraktar E, Ivan C, Filant J, Silva A, Aslan B, Denizli M, Mitra R, Ozpolat B, Calin GA, Sood AK, Abd-Ellah MF, Helal GK, Berestein GL. **Exosomal miR-940 maintains SRC-mediated oncogenic activity in cancer cells: a possible role for exosomal disposal of tumor suppressor miRNAs.** *Oncotarget* 8(12):20145-20164, 2017. PMID: PMC5386751.
61. Rodriguez-Aguayo C, Monroig PDC, Redis RS, Bayraktar E, Almeida MI, Ivan C, Fuentes-Mattei E, Rashed MH, Chavez-Reyes A, Ozpolat B, Mitra R, Sood AK, Calin GA, Lopez-Berestein G. **Regulation of hnRNPA1 by microRNAs controls the miR-18a-K-RAS axis in chemotherapy-resistant ovarian cancer.** *Cell Discov* 3:17029, 2017. PMID: PMC5594916.
62. Roy-Chowdhuri S, Chen H, Singh RR, Krishnamurthy S, Patel KP, Routbort MJ, Manekia J, Barkoh BA, Yao H, Sabir S, Broaddus RR, Medeiros LJ, Staerckel G, Stewart J, Luthra R. **Concurrent fine needle aspirations and core needle biopsies: a comparative study of substrates for next-generation sequencing in solid organ malignancies.** *Mod Pathol* 30(4):499-508, 2017. PMID: 28084342.
63. Rynne-Vidal A, Au-Yeung CL, Jiménez-Heffernan JA, Pérez-Lozano ML, Cremades-Jimeno L, Bárcena C, Cristóbal-García I, Fernández-Chacón C, Yeung TL, Mok SC, Sandoval P, López-Cabrera M. **Mesothelial-to-mesenchymal transition as a possible therapeutic target in peritoneal metastasis of ovarian cancer.** *J Pathol* 242(2):140-151, 2017. PMID: PMC5468005.

64. Sabir SH, Krishnamurthy S, Gupta S, Mills GB, Wei W, Cortes AC, Mills Shaw KR, Luthra R, Wallace MJ. **Characteristics of percutaneous core biopsies adequate for next generation genomic sequencing.** PLoS One 12(12):e0189651, 2017. PMCID: PMC5744968.
65. Sánchez NS, Mills GB, Mills Shaw KR. **Precision oncology: neither a silver bullet nor a dream.** Pharmacogenomics 18(16):1525-1539, 2017. PMID: 29061079.
66. Sans M, Gharpure K, Tibshirani R, Zhang J, Liang L, Liu J, Young JH, Dood RL, Sood AK, Eberlin LS. **Metabolic Markers and Statistical Prediction of Serous Ovarian Cancer Aggressiveness by Ambient Ionization Mass Spectrometry Imaging.** Cancer Res 77(11):2903-2913, 2017. PMCID: PMC5750373.
67. Skates SJ, Greene MH, Buys SS, Mai PL, Brown P, Piedmonte M, Rodriguez G, Schorge JO, Sherman M, Daly MB, Rutherford T, Brewster WR, O'Malley DM, Partridge E, Boggess J, Drescher CW, Isaacs C, Berchuck A, Domchek S, Davidson SA, Edwards R, Elg SA, Wakeley K, Phillips KA, Armstrong D, Horowitz I, Fabian CJ, Walker J, Sluss PM, Welch W, Minasian L, Horick NK, Kasten CH, Nayfield S, Alberts D, Finkelstein DM, Lu KH. **Early Detection of Ovarian Cancer using the Risk of Ovarian Cancer Algorithm with Frequent CA125 Testing in Women at Increased Familial Risk - Combined Results from Two Screening Trials.** Clin Cancer Res 23(14):3628-3637, 2017. PMCID: PMC5726402.
68. Smith JA, Mathew L, Burney M, Nyshadham P, Coleman RL. **Corrigendum to 'Equivalency challenge: evaluation of Lipodox® as the generic equivalent for Doxil® in a human ovarian cancer orthotropic mouse model' [Gynecol. Oncol. 141 (2016) 357-363].** Gynecol Oncol 144(2):448, 2017. PMID: 28089052.
69. Song M, Lee H, Nam MH, Jeong E, Kim S, Hong Y, Kim N, Yim HY, Yoo YJ, Kim JS, Kim JS, Cho YY, Mills GB, Kim WY, Yoon S. **Loss-of-function screens of druggable targetome against cancer stem-like cells.** FASEB J 31(2):625-635, 2017. PMCID: PMC5240669.
70. Städler N, Dondelinger F, Hill SM, Akbani R, Lu Y, Mills GB, Mukherjee S. **Molecular heterogeneity at the network level: high-dimensional testing, clustering and a TCGA case study.** Bioinformatics 33(18):2890-2896, 2017. PMCID: PMC5590725.
71. Suidan RS, Ramirez PT, Sarasohn DM, Teitcher JB, Iyer RB, Zhou Q, Iasonos A, Denesopolis J, Zivanovic O, Long Roche KC, Sonoda Y, Coleman RL, Abu-Rustum NR, Hricak H, Chi DS. **A multicenter assessment of the ability of preoperative computed tomography scan and CA-125 to predict gross residual disease at primary debulking for advanced epithelial ovarian cancer.** Gynecol Oncol 145(1):27-31, 2017. PMCID: PMC5387995.
72. Sun C, Fang Y, Yin J, Chen J, Ju Z, Zhang D, Chen X, Vellano CP, Jeong KJ, Ng PK, Eterovic AKB, Bhola NH, Lu Y, Westin SN, Grandis JR, Lin SY, Scott KL, Peng G, Brugge J, Mills GB. **Rational combination therapy with PARP and MEK inhibitors capitalizes on therapeutic liabilities in RAS mutant cancers.** Sci Transl Med 9(392), 2017. PMID: 28566428.
73. Swisher EM, Lin KK, Oza AM, Scott CL, Giordano H, Sun J, Konecny GE, Coleman RL, Tinker AV, O'Malley DM, Kristeleit RS, Ma L, Bell-McGuinn KM, Brenton JD, Cragun JM, Oaknin A, Ray-Coquard I, Harrell MI, Mann E, Kaufmann SH, Floquet A, Leary A, Harding TC, Goble S, Maloney L, Isaacson J, Allen AR, Rolfe L, Yelensky R, Raponi M, McNeish IA. **Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial.** Lancet Oncol 18(1):75-87, 2017. PMID: 27908594.
74. Takiar V, Ip CK, Gao M, Mills GB, Cheung LW. **Neomorphic mutations create therapeutic challenges in cancer.** Oncogene 36(12):1607-1618, 2017. PMID: 27841866.
75. Taylor C, Mannion D, Miranda F, Karaminejadranjbar M, Herrero-Gonzalez S, Hellner K, Zheng Y, Bartholomeusz G, Bast RC Jr, Ahmed AA. **Loss of PFKFB4 induces cell death in mitotically arrested ovarian cancer cells.** Oncotarget 8(11):17960-17980, 2017. PMCID: PMC5392300.

76. Vafaee F, Colvin EK, Mok SC, Howell VM, Samimi G. **Functional prediction of long non-coding RNAs in ovarian cancer-associated fibroblasts indicate a potential role in metastasis.** *Sci Rep* 7(1):10374, 2017. PMID: PMC5583324.
77. Wagner MJ, Mitra R, McArthur MJ, Baze W, Barnhart K, Wu SY, Rodriguez-Aguayo C, Zhang X, Coleman RL, Lopez-Berestein G, Sood AK. **Preclinical Mammalian Safety Studies of EPHARNA (DOPC Nanoliposomal EphA2-Targeted siRNA).** *Mol Cancer Ther* 16(6):1114-1123, 2017. PMID: PMC5457703.
78. Wang C, Gu C, Jeong KJ, Zhang D, Guo W, Lu Y, Ju Z, Panupinthu N, Yang JY, Gagea MM, Ng PK, Zhang F, Mills GB. **YAP/TAZ-Mediated Upregulation of GAB2 Leads to Increased Sensitivity to Growth Factor-Induced Activation of the PI3K Pathway.** *Cancer Res* 77(7):1637-1648, 2017. PMID: 28202507.
79. Westin SN, Coleman RL. **Individualized Medicine in Ovarian Cancer: Are We There Yet?** *Gynecol Oncol* 144(2):229-231, 2017. PMID: 28089051.
80. Yang WL, Gentry-Maharaj A, Simmons A, Ryan A, Fourkala EO, Lu Z, Baggerly KA, Zhao Y, Lu KH, Bowtell D, Jacobs I, Skates SJ, He WW, Menon U, Bast RC Jr, AOCs Study Group. **Elevation of TP53 Autoantibody Before CA125 in Preclinical Invasive Epithelial Ovarian Cancer.** *Clin Cancer Res* 23(19):5912-5922, 2017. PMID: PMC5626590.
81. Yang WL, Lu Z, Bast RC Jr. **The role of biomarkers in the management of epithelial ovarian cancer.** *Expert Rev Mol Diagn* 17(6):577-591, 2017. PMID: 28468520.
82. Yeung TL, Leung CS, Wong KK, Gutierrez-Hartmann A, Kwong J, Gershenson DM, Mok SC. **ELF3 is a negative regulator of epithelial-mesenchymal transition in ovarian cancer cells.** *Oncotarget* 8(10):16951-16963, 2017. PMID: PMC5370013.
83. Yi S, Lin S, Li Y, Zhao W, Mills GB, Sahni N. **Functional variomics and network perturbation: connecting genotype to phenotype in cancer.** *Nat Rev Genet* 18(7):395-410, 2017. PMID: 28344341.
84. Zervantonakis IK, Iavarone C, Chen HY, Selfors LM, Palakurthi S, Liu JF, Drapkin R, Matulonis U, Levenson JD, Sampath D, Mills GB, Brugge JS. **Systems analysis of apoptotic priming in ovarian cancer identifies vulnerabilities and predictors of drug response.** *Nat Commun* 8(1):365, 2017. PMID: PMC5573720.
85. Zhang Y, Kwok-Shing Ng P, Kucherlapati M, Chen F, Liu Y, Tsang YH, de Velasco G, Jeong KJ, Akbani R, Hadjipanayis A, Pantazi A, Bristow CA, Lee E, Mahadeshwar HS, Tang J, Zhang J, Yang L, Seth S, Lee S, Ren X, Song X, Sun H, Seidman J, Luquette LJ, Xi R, Chin L, Protopopov A, Westbrook TF, Shelley CS, Choueiri TK, Ittmann M, Van Waes C, Weinstein JN, Liang H, Henske EP, Godwin AK, Park PJ, Kucherlapati R, Scott KL, Mills GB, Kwiatkowski DJ, Creighton CJ. **A Pan-Cancer Proteogenomic Atlas of PI3K/AKT/mTOR Pathway Alterations.** *Cancer Cell* 31(6):820-832.e3, 2017. PMID: PMC5502825.
86. Zhao W, Fitzgibbon M, Bergan L, Clegg N, Crispin D, Mills GB, McIntosh M. **Identifying Abundant Immunotherapy and Other Targets in Solid Tumors: Integrating RNA-seq and Mass Spectrometry Proteomics Data Sets.** *Cancer J* 23(2):108-114, 2017. PMID: 28410298.
87. Zhao W, Li J, Mills GB. **Functional proteomic characterization of cancer cell lines.** *Oncoscience* 4(5-6):41-42, 2017. PMID: PMC5538845.
88. Zhou J, Alfraidi A, Zhang S, Santiago-O'Farrill JM, Yerramreddy Reddy VK, Alsaadi A, Ahmed AA, Yang H, Liu J, Mao W, Wang Y, Takemori H, Vankayalapati H, Lu Z, Bast RC Jr. **A Novel Compound ARN-3236 Inhibits Salt-Inducible Kinase 2 and Sensitizes Ovarian Cancer Cell Lines and Xenografts to Paclitaxel.** *Clin Cancer Res* 23(8):1945-1954, 2017. PMID: PMC5436602.

89. Zoeller JJ, Bronson RT, Selfors LM, Mills GB, Brugge JS. **Niche-localized tumor cells are protected from HER2-targeted therapy via upregulation of an anti-apoptotic program in vivo.** NPJ Breast Cancer 3:18, 2017. PMID: PMC5460247.
90. Zuo X, Xu W, Xu M, Tian R, Moussalli MJ, Mao F, Zheng X, Wang J, Morris JS, Gagea M, Eng C, Kopetz S, Maru DM, Rashid A, Broaddus R, Wei D, Hung MC, Sood AK, Shureiqi I. **Metastasis regulation by PPARD expression in cancer cells.** JCI Insight 2(1):e91419, 2017. PMID: PMC5214933.